Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial

  title={Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial},
  author={Macarena I de la Fuente and Howard Colman and Mark Rosenthal and Brian Andrew Van Tine and Danijela Levacic and Tobias Walbert and Hui Kong Gan and Mar{\'i}a Vieito and Mohammed M Milhem and Kate Lipford and Sanjeev Forsyth and Sylvie Guichard and Yelena Mikhailov and Alexander Sedkov and Julie A. Brevard and Patrick F Kelly and Hesham Mohamed and Varun Monga},
  pages={146 - 156}
Abstract Background Olutasidenib (FT-2102) is a highly potent, orally bioavailable, brain-penetrant and selective inhibitor of mutant isocitrate dehydrogenase 1 (IDH1). The aim of the study was to determine the safety and clinical activity of olutasidenib in patients with relapsed/refractory gliomas harboring an IDH1R132X mutation. Methods This was an open-label, multicenter, nonrandomized, phase Ib/II clinical trial. Eligible patients (≥18 years) had histologically confirmed IDH1R132X-mutated… 

Figures and Tables from this paper

Targeting IDH1/IDH2 mutations in gliomas

Experimental therapeutic approaches targeting IDH mutations in gliomas including small-molecule inhibitors, immunotherapies, and agents targeting mutant IDH-induced epigenetic and metabolic vulnerabilities are reviewed.

Olutasidenib: First Approval

The milestones in the development of olutasidenib leading to this first approval for R/R AML are summarized.

Overview of Cancer Metabolism and Signaling Transduction

The relationship between cancer metabolism and the signal transduction pathways is investigated, and the recent developments in anti-cancer therapy that target metabolism are highlighted.

Metabolic reprograming of cancer as a therapeutic target.

Crosstalk between metabolic reprogramming and epigenetics in cancer: updates on mechanisms and therapeutic opportunities

The central mechanisms by which epigenetics and metabolism reciprocally modulate each other in cancer are summarized and elaborate upon and update the major contributions of the interplays between epigenetic aberrations and metabolic rewiring to cancer initiation and development.

A new player in IDH1 mutated myeloid neoplasias.



Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients with Acute Myeloid Leukemia Treated in a Phase 1 Dose Escalation and Expansion Study

This year's finalists were Justin M. Watts, Maria R. Baer, Jay Yang, Thomas Prebet, Sangmin Lee, Gary J. Schiller, Shira N. Dinner, and Sylvie Guichard.

Effect of olutasidenib (FT-2102) on complete remissions in patients with relapsed/refractory (R/R) mIDH1 acute myeloid leukemia (AML): Results from a planned interim analysis of a phase 2 clinical trial.

Olutasidenib was well tolerated and induced durable CR in a subset of high-risk R/R m IDH1 AML pts and clinical benefit, per DOR and OS, extended beyond CR+CRh responders.

Olutasidenib (FT-2102) Induces Rapid Remissions in Patients with IDH1-Mutant Myelodysplastic Syndrome: Results of Phase 1/2 Single Agent Treatment and Combination with Azacitidine

This research presents a novel approach to tumorigenicity called “ ‘cell reprograming’,’ which allows for the small number of cells to be attacked by the immune system through a simple ‘ ‘ T-cell ’ attack’.

Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial

Vorasidenib was well tolerated and showed preliminary antitumor activity in patients with recurrent or progressive nonenhancing mIDH LGG, and showed a favorable safety profile in the glioma cohort.

Olutasidenib (FT-2102) in Combination with Azacitidine Induces Durable Complete Remissions in Patients with mIDH1 Acute Myeloid Leukemia

Results of an ongoing phase 2 trial in pts receiving olutasidenib in combination with AZA, a potent, selective, oral, small molecule inhibitor of mutant isocitrate dehydrogenase 1, show synergistic effects with mIDH1 inhibitors on releasing differentiation block in m IDH leukemia models in vitro.

Ivosidenib in Isocitrate Dehydrogenase 1–Mutated Advanced Glioma

In patients with mIDH1 advanced glioma, ivosidenib 500 mg once per day was associated with a favorable safety profile, prolonged disease control, and reduced growth of nonenhancing tumors.

IDH1 Non-Canonical Mutations and Survival in Patients with Glioma

The presence of non-canonical IDH1 mutations could be associated with improved survival among patients with IDH 1 mutated grade II–III glioma.

IDH1 mutation of gliomas with long-term survival analysis.

IDH1 mutation was an independent positive prognostic factor in LOs and AOs, especially in the absence of p53 overexpression, and was not correlated with common genetic profiles that affect patient prognosis, including MGMT methylation, 1p 19q co-deletion, PTEN loss and EGFR amplification in L Os, AOs and GBMs.

Structure-based design and identification of FT-2102 (olutasidenib), a potent mutant-selective IDH1 inhibitor.

Inhibition of mutant IDH1 is being evaluated clinically as a treatment option for oncology. Here we describe structure-based design and optimization of quinoline lead compounds to identify FT-2102, a